...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits

GAC, 

I think we are saying the same thing. We are both saying that we won't hear any results for any BETonMACE trial endpoint until the top-line data announcement.

"Of course we don't know what "selected" secondary endpoints might be released...I've been focused on secondary outcomes for CKD and Cognition. Are there others?"

Yes there are others. See here

BDAZ

Share
New Message
Please login to post a reply